
DNA SEQ provides reports that help clinicians tailor cancer treatment by matching a patient’s genomic profile to targeted therapies. The core mechanism uses a machine learning algorithm trained on structural genomics and a proprietary crystal structure library to filter and rank therapy options based on crystallography. It operates as a B2B service for healthcare providers, delivering genomic reports and relying on whole-exome sequencing as the basis for analysis. The method aims to expand access to precision oncology, scalable across cancer types and treatment options.

DNA SEQ provides reports that help clinicians tailor cancer treatment by matching a patient’s genomic profile to targeted therapies. The core mechanism uses a machine learning algorithm trained on structural genomics and a proprietary crystal structure library to filter and rank therapy options based on crystallography. It operates as a B2B service for healthcare providers, delivering genomic reports and relying on whole-exome sequencing as the basis for analysis. The method aims to expand access to precision oncology, scalable across cancer types and treatment options.
Focus: Precision oncology using sequencing, 3D crystallography and machine learning
Founded: 2013 (May)
Headquarters: San Diego, United States
Business model: B2B genomic reports for clinicians (whole-exome sequencing–based)
Precision oncology; identifying drug resistance and matching patients to targeted therapies
2013
Biotechnology
1000000